519 related articles for article (PubMed ID: 31035599)
1. Molecular Biomarkers in Fragile X Syndrome.
Zafarullah M; Tassone F
Brain Sci; 2019 Apr; 9(5):. PubMed ID: 31035599
[TBL] [Abstract][Full Text] [Related]
2. Fragile X syndrome.
Hagerman RJ; Berry-Kravis E; Hazlett HC; Bailey DB; Moine H; Kooy RF; Tassone F; Gantois I; Sonenberg N; Mandel JL; Hagerman PJ
Nat Rev Dis Primers; 2017 Sep; 3():17065. PubMed ID: 28960184
[TBL] [Abstract][Full Text] [Related]
3. Modeling fragile X syndrome in the Fmr1 knockout mouse.
Kazdoba TM; Leach PT; Silverman JL; Crawley JN
Intractable Rare Dis Res; 2014 Nov; 3(4):118-33. PubMed ID: 25606362
[TBL] [Abstract][Full Text] [Related]
4. Fragile X syndrome: From protein function to therapy.
Bagni C; Oostra BA
Am J Med Genet A; 2013 Nov; 161A(11):2809-21. PubMed ID: 24115651
[TBL] [Abstract][Full Text] [Related]
5. microRNAs and Fragile X Syndrome.
Lin SL
Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
[TBL] [Abstract][Full Text] [Related]
6. The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study.
Jalnapurkar I; Frazier JA; Roth M; Cochran DM; Foley A; Merk T; Venuti L; Ronco L; Raines S; Cadavid D
J Neurodev Disord; 2022 Dec; 14(1):57. PubMed ID: 36494616
[TBL] [Abstract][Full Text] [Related]
7. Synaptic vesicle dynamic changes in a model of fragile X.
Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S
Mol Autism; 2016; 7():17. PubMed ID: 26933487
[TBL] [Abstract][Full Text] [Related]
8. Non-coding RNA in Fragile X Syndrome and Converging Mechanisms Shared by Related Disorders.
Zhou Y; Hu Y; Sun Q; Xie N
Front Genet; 2019; 10():139. PubMed ID: 30881383
[TBL] [Abstract][Full Text] [Related]
9. FMRP Levels in Human Peripheral Blood Leukocytes Correlates with Intellectual Disability.
Roth M; Ronco L; Cadavid D; Durbin-Johnson B; Hagerman RJ; Tassone F
Diagnostics (Basel); 2021 Sep; 11(10):. PubMed ID: 34679478
[TBL] [Abstract][Full Text] [Related]
10. CGG-repeat dynamics and
Zhou Y; Kumari D; Sciascia N; Usdin K
Mol Autism; 2016; 7():42. PubMed ID: 27713816
[TBL] [Abstract][Full Text] [Related]
11. A Genotype-Phenotype Study of High-Resolution
Budimirovic DB; Schlageter A; Filipovic-Sadic S; Protic DD; Bram E; Mahone EM; Nicholson K; Culp K; Javanmardi K; Kemppainen J; Hadd A; Sharp K; Adayev T; LaFauci G; Dobkin C; Zhou L; Brown WT; Berry-Kravis E; Kaufmann WE; Latham GJ
Brain Sci; 2020 Sep; 10(10):. PubMed ID: 33008014
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Reactivation of the Silenced
Kumari D; Gazy I; Usdin K
Brain Sci; 2019 Feb; 9(2):. PubMed ID: 30759772
[TBL] [Abstract][Full Text] [Related]
13. Fragile X spectrum disorders.
Lozano R; Rosero CA; Hagerman RJ
Intractable Rare Dis Res; 2014 Nov; 3(4):134-46. PubMed ID: 25606363
[TBL] [Abstract][Full Text] [Related]
14. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
15. Modeling Fragile X Syndrome in
Drozd M; Bardoni B; Capovilla M
Front Mol Neurosci; 2018; 11():124. PubMed ID: 29713264
[TBL] [Abstract][Full Text] [Related]
16. Clinical, molecular, and pharmacological aspects of FMR1 related disorders.
Pugin A; Faundes V; Santa María L; Curotto B; Aliaga S; Salas I; Soto P; Bravo P; Peña MI; Alliende MA
Neurologia; 2017 May; 32(4):241-252. PubMed ID: 25529181
[TBL] [Abstract][Full Text] [Related]
17. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
[TBL] [Abstract][Full Text] [Related]
18. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
20. Fragile X syndrome and fragile X-associated tremor ataxia syndrome.
Hall DA; Berry-Kravis E
Handb Clin Neurol; 2018; 147():377-391. PubMed ID: 29325626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
